Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

A.J.M. van den Eertwegh; J.P. Versluis; H.P. van den Berg; S.J.A.M. Santegoets; R.J.A. van Moorselaar; T.M. van der Sluis; H.E. Gall; T.C. Harding; K. Jooss; I. Lowy; H.M. Pinedo; R.J. Scheper; A.G.M. Stam; B.M.E. von Blomberg; T.D. de Gruijl; K. Hege; N. Sacks; W.R. Gerritsen

doi:https://doi.org/10.1016/S1470-2045(12)70007-4

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

A.J.M. van den Eertwegh, J.P. Versluis, H.P. van den Berg, S.J.A.M. Santegoets, R.J.A. van Moorselaar, T.M. van der Sluis, H.E. Gall, T.C. Harding, K. Jooss, I. Lowy, H.M. Pinedo, R.J. Scheper, A.G.M. Stam, B.M.E. von Blomberg, T.D. de Gruijl, K. Hege, N. Sacks, W.R. Gerritsen

Research output: Contribution to journal › Article › Academic › peer-review

309 Citations (Scopus)

Original language	English
Pages (from-to)	509-517
Journal	lancet oncology
Volume	13
Issue number	5
DOIs	https://doi.org/10.1016/S1470-2045(12)70007-4
Publication status	Published - 2012

Access to Document

https://doi.org/10.1016/S1470-2045(12)70007-4

Cite this

van den Eertwegh, A. J. M., Versluis, J. P., van den Berg, H. P., Santegoets, S. J. A. M., van Moorselaar, R. J. A., van der Sluis, T. M., Gall, H. E., Harding, T. C., Jooss, K., Lowy, I., Pinedo, H. M., Scheper, R. J., Stam, A. G. M., von Blomberg, B. M. E., de Gruijl, T. D., Hege, K., Sacks, N., & Gerritsen, W. R. (2012). Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. lancet oncology, 13(5), 509-517. https://doi.org/10.1016/S1470-2045(12)70007-4

@article{9951223c74824918aef048039ec71e9a,

title = "Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial",

author = "{van den Eertwegh}, A.J.M. and J.P. Versluis and {van den Berg}, H.P. and S.J.A.M. Santegoets and {van Moorselaar}, R.J.A. and {van der Sluis}, T.M. and H.E. Gall and T.C. Harding and K. Jooss and I. Lowy and H.M. Pinedo and R.J. Scheper and A.G.M. Stam and {von Blomberg}, B.M.E. and {de Gruijl}, T.D. and K. Hege and N. Sacks and W.R. Gerritsen",

year = "2012",

doi = "https://doi.org/10.1016/S1470-2045(12)70007-4",

language = "English",

volume = "13",

pages = "509--517",

journal = "lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "5",

}

van den Eertwegh, AJM, Versluis, JP, van den Berg, HP, Santegoets, SJAM, van Moorselaar, RJA , van der Sluis, TM, Gall, HE, Harding, TC, Jooss, K, Lowy, I, Pinedo, HM, Scheper, RJ , Stam, AGM, von Blomberg, BME, de Gruijl, TD, Hege, K, Sacks, N & Gerritsen, WR 2012, 'Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial', lancet oncology, vol. 13, no. 5, pp. 509-517. https://doi.org/10.1016/S1470-2045(12)70007-4

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. / van den Eertwegh, A.J.M.; Versluis, J.P.; van den Berg, H.P. et al.
In: lancet oncology, Vol. 13, No. 5, 2012, p. 509-517.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

AU - van den Eertwegh, A.J.M.

AU - Versluis, J.P.

AU - van den Berg, H.P.

AU - Santegoets, S.J.A.M.

AU - van Moorselaar, R.J.A.

AU - van der Sluis, T.M.

AU - Gall, H.E.

AU - Harding, T.C.

AU - Jooss, K.

AU - Lowy, I.

AU - Pinedo, H.M.

AU - Scheper, R.J.

AU - Stam, A.G.M.

AU - von Blomberg, B.M.E.

AU - de Gruijl, T.D.

AU - Hege, K.

AU - Sacks, N.

AU - Gerritsen, W.R.

PY - 2012

Y1 - 2012

U2 - https://doi.org/10.1016/S1470-2045(12)70007-4

DO - https://doi.org/10.1016/S1470-2045(12)70007-4

M3 - Article

SN - 1470-2045

VL - 13

SP - 509

EP - 517

JO - lancet oncology

JF - lancet oncology

IS - 5

ER -

van den Eertwegh AJM, Versluis JP, van den Berg HP, Santegoets SJAM, van Moorselaar RJA , van der Sluis TM et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. lancet oncology. 2012;13(5):509-517. doi: https://doi.org/10.1016/S1470-2045(12)70007-4